

cytochrome c to oxygen [7]. This finding tied p66 and its effect on longevity to ROS and mitochondria, in perfect agreement with Harman's theories; accordingly, studies performed on p66KO mice involved p66 in a number of typical age-related diseases, including vascular diabetic complication and atherosclerosis, already suspected to be caused by excess oxidative stress [8]. Interestingly, in keeping with initial predictions, insulin signaling was indeed found to be defective in p66-deficient cells and mice, but that was again related to the molecule's capacity to generate ROS, that facilitate tyrosine kinase signaling by transient and reversible inhibition of tyrosine phosphatases [9].

Accumulation of cellular and tissue oxidative damage, however, may not represent the only, or even the most important, mechanism underlying body senescence and limitation of lifespan. Mounting evidence indicate that effects of calorie restriction on longevity involve a number of nutrient-sensing molecular networks that regulate, beside ROS generation and scavenging, also DNA repair, inflammation, cell proliferation and body growth (i.e. accumulation of biomass) [10]. One of these evolutionarily conserved networks involves the sirtuin family of NAD⁺ dependent histone deacetylases (sirtuin 1 through 7 in mammals) that regulate chromatin remodelling and gene transcription in response to cellular energy status [11]. Another major nutrient-sensing pathway is centered on the TOR (Target of Rapamycin) kinase and its downstream cascade. In mammalian cells, mammalian TOR regulates ribosomal protein synthesis, cell growth, cell cycle progression, autophagy and mitochondrial function in response to the availability of amino acids and the intracellular levels of ATP. Additionally, mTOR is activated by growth factor receptors. Including, of course, the insulin receptor [12].

Several lines of evidence indicate that nutrient and insulin-dependent regulation of TOR and its downstream cascade may play a central role in aging and in the nutritional control of lifespan. In yeast, flies and worms, hypomorphic mutations in this cascade extend longevity [10]. Even more interestingly, the mTOR inhibitor Rapamycin extends lifespan in mice and prevents age-related diseases [13], and so does genetic deletion of the ribosomal S6 kinase (S6K), a major downstream effector of mTOR [14]. Thus, inactivation of the mTOR pathway mimics the beneficial effect of calorie restriction in rodents, clearly indicating that mTOR-dependent signaling contributes to longevity determination by nutrients in mammals. Again, inhibition of TOR may lead to increased antioxidant defenses, as observed in yeast and flies [15],

but could also promote autophagy and reduce intracellular accumulation of pathologic proteins, that eventually leads to Endoplasmic Reticulum (ER) stress and tissue aging [16]. Notably, accumulation of misfolded proteins underlies typical senescence-associated pathologies like Alzheimer's and vascular amyloidosis, while ER stress contributes to insulin resistance and Metabolic Syndrome, another age-dependent disease [17].

Is there a relationship between p66-dependent aging and the regulation of longevity by nutrients, through the mTOR/S6K cascade? Or, in other words, does the mTOR/S6K cascade contribute to p66 effects on mouse lifespan? Recent work performed in our laboratory tried to address this seemingly relevant question [18].

We were initially interested in determining whether p66shc may have a role in insulin resistance, the signaling dysfunction underlying glucose intolerance and type 2 diabetes associated with overnutrition and overweight. The question was legitimated by increasing evidence of a role for reactive oxygen species in insulin desensitization [19], and by our previous observation of reduced liver steatosis, a major inducer of insulin-resistance, in p66KO mice [20]. We indeed found that obese (LepOb, leptin deficient) mice devoid of p66, although gaining nearly as much weight as their p66-proficient littermates, remained remarkably responsive to insulin and were significantly protected from diabetes. Importantly, this finding correlated with reduced levels of phosphorylation of S6K in the adipose tissue; additionally, isolated adipocytes from p66KO obese mice displayed reduced S6K activity and preserved insulin responsiveness compared to p66 WT cells, and p66KO preadipocytes were resistant to the insulin-desensitizing effect of excess fatty acids *in vitro*.

These findings fitted with the current model whereby excess nutrient (glucose and Free Fatty Acids) and chronic hyperinsulinemia downregulate insulin response in target tissues by hyperactivating S6K, that in turn leads to serine phosphorylation and proteasomal degradation of the major insulin transducer IRS-1 [21]. p66 would participate in this circuitry by somehow stimulating S6K. Accordingly, we showed that overexpression of p66shc in 3T3L1 adipocytes leads to hyperactivation of S6K and to hyperphosphorylation of IRS on serine residues. Further molecular dissection of these biochemical events also revealed that p66shc forms a complex with S6K 1 and IRS-1, thus facilitating the signal-inhibitory interaction between the two molecules. To our surprise, these effects of p66 were largely independent from changes in the intracellular redox state, or from the redox properties of p66 itself,

Apart from prevention of glucose dysmetabolism, all the S6K-related mechanisms for lifespan extension may operate, in view of our findings, in p66KO mice. For instance, reduced protein translation may attenuate ER stress in critical tissues and reduce progression and severity of age-related diseases due to accumulation of misfolded proteins. While this possibility deserves to be tested in appropriate model systems (such as mice prone to Alzheimer's disease crossed to p66KO mice), we have preliminary evidence that overexpression of p66shc in preadipocytes and kidney cells increases ER stress in parallel with hyperactivation of S6K.

Along similar lines, increased autophagy, due to S6K attenuation, may contribute to the long-lived phenotype of p66 deficient animals, another possibility to be verified.

Finally, prevention of cancer contributes to lifespan extension by calorie restriction and S6K blockade. This may be true also in p66KO mice. Interestingly, in spite of p66shc operating in the p53-initiated apoptotic pathway [22], no increase in tumor incidence has been described in this mouse strain. Based on our prediction such incidence may even be lower than in wild type animals, due, at least in part, to reduced mTOR/S6K signaling in cancer cells. This is again a testable hypothesis.

Can these views be reconciled with current, "ROS-centric" model for lifespan limitation by p66 [23]?

In principle, ROS can operate both upstream and downstream of the TOR cascade. In one scenario, p66 action on S6K may lead to increased mitochondrial metabolism and as a consequence to a rise of mitochondrial ROS [24], as observed in cells where p66shc is overexpressed [2]. In simple terms, mTOR/S6K may mediate, at least in part, the pro-oxidant action of p66 (Figure 1B).

More intriguingly, ROS may act upstream of the p66/S6K module, since p66shc not only generates ROS, but is also stimulated by oxidants [2]. For instance, in fibroblasts exposed to oxidative stress, PI3K/Akt activation by ROS is mediated, at least to some extent, by p66shc [25]; Akt can, in turn, activate mTOR. ROS are also generated in mitochondria in response to energy substrates; these species may increase the phosphorylation/expression level of p66, thereby promoting its (redox-independent) stimulatory action on S6K. This would represent an intriguing alternative route for nutrients to signal, *via* mitochondria, ROS and p66shc, to the mTOR/S6K cascade (Figure 1A). Of note, phosphorylation of p66, a modification that correlates

with its biological activity, was found to be increased in pre-adipocytes exposed to hyperglycemia or excess FFA, as if p66 were actually behaving as a sensor of nutrient abundance in these cellular contexts [17].

In all the above scenarios, p66, S6K and ROS lie on the same nutrient sensitive pathway, mechanistically linked to aging and potentially targetable by calorie restriction (Figure 1 A and B).

In conclusion, the observation that p66shc contributes to S6K activation in response to glucose, amino acids and insulin, supports the concept that aging and age-related diseases are driven by TOR (not by ROS) and p66shc accelerates aging by activating TOR [26]; revealing the existence of a novel nutrient-regulated pathway to senescence, in which p66shc works as an adaptor (what else?) between ROS and TOR.

ACKNOWLEDGEMENTS

I wish to thank Prof. Tommaso Galeotti for constant encouragement and members of the lab for helpful discussions. The original work described in this article was supported by the European Association for the Study of Diabetes (EASD), EFSD/GSK Programme for the Study of Metabolic Toxicity in Diabetes (to G.P) and the Italian Ministry of University and Research and Catholic University (MIUR ex 60% linea D1 to G.P.).

CONFLICT OF INTERESTS STATEMENT

The author of this manuscript has no conflict of interests to declare.

REFERENCES

1. Guarente L, Kenyon C. Genetic pathways that regulate aging in model organisms. *Nature*. 2000; 408:255-262.
2. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L, Pelicci PG. The p66shc adaptor protein controls oxidative stress response and life span in mammals. *Nature*. 1999; 402:309-313.
3. Giorgetti S, Pelicci PG, Pelicci G, Van Obberghen E. () Involvement of Src homology/collagen (SHC) proteins in signaling through the insulin receptor and the insulin-like-growth-factor-I-receptor. *Eur J Biochem*. 1994; 223:195-202.
4. Lithgow GJ, Gill MS. Physiology: Cost-free longevity in mice? *Nature* 2003; 421:125-126.
5. Harman D. A biologic clock: the mitochondria?. *Journal of the American Geriatrics Society* 1972; 20:145-147.
6. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffey PJ, Huang TT, Bos JL, Medema RH, Burgering BM. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. *Nature*. 2002; 419:316-321.

7. Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, et al. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. *Cell*. 2005; 122:221-233.
8. Cosentino F, Francia P, Camici GG, Pelicci PG, Lüscher TF, Volpe M. Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein. *Arterioscler Thromb Vasc Biol*. 2008; 28:622-628.
9. Berniakovich I, Trinei M, Stendardo M, Migliaccio E, Minucci S, et al. p66Shc-generated oxidative signal promotes fat accumulation. *J Biol Chem*. 2008; 283:34283-34293.
10. Fontana L, Partridge L, Longo VD. Extending healthy life span--from yeast to humans. *Science*. 2010 328:321-326.
11. Guarente L. Sirtuins in aging and disease. *Cold Spring Harb Symp Quant Biol*. 2007; 72:483-438.
12. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. *Curr Opin Cell Biol*. 2005; 17:596-603.
13. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature*. 2009; 406:392-396.
14. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, Woods A, Robinson IC, Schuster E, Batterham RL, Kozma SC, Thomas G, Carling D, Okkenhaug K, Thornton JM, Partridge L, Gems D, Withers DJ. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. *Science*. 2009; 326:140-144.
15. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge L. Mechanisms of life span extension by rapamycin in the fruit fly *Drosophila melanogaster*. *Cell Metab*. 2010; 11:35-46.
16. Gregersen N, Bross P, Vang S, Christensen JH. Protein misfolding and human disease. *Annu Rev Genomics Hum Genet*. 2006; 7:103-124.
17. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Görgün C, Glimcher LH, Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science*. 2004; 306:457-461.
18. Ranieri SC, Fusco S, Panieri E, Labate V, Mele M, Tesori V, Ferrara AM, Maulucci G, De Spirito M, Martorana GE, Galeotti T, Pani G. Mammalian life-span determinant p66shcA mediates obesity-induced insulin resistance. *Proc Natl Acad Sci U S A*. 2010 Jul 12. [Epub ahead of print]
19. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. *Nature*. 2006; 440:944-948.
20. Koch OR, Fusco S, Ranieri SC, Maulucci G, Palozza P, Larocca LM, Cravero AA, Farre' SM, De Spirito M, Galeotti T, Pani G. Role of the life span determinant P66(shcA) in ethanol-induced liver damage. *Lab Invest*. 2008; 88:750-760.
21. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. *Cell Metab*. 2006; 3:393-402.
22. Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, et al. A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. *Oncogene*. 2002; 21:3872-3878.
23. Trinei M, Berniakovich I, Beltrami E, Migliaccio E, Fassina A, Pelicci P, Giorgio M. P66Shc signals to age. *Aging*. 2009; 1:503-510.
24. Schieke SM, Finkel T. Mitochondrial signaling, TOR, and life span. *Biol Chem*. 2006; 387:1357-1361.
25. Nemoto S, Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signalling pathway. *Science*. 2002; 295:2450-2452.
26. Blagosklonny MV. Aging: ROS or TOR. *Cell Cycle*. 2008; 7:3344-3354.